中文版 | English

在结果中检索

HFCAS OpenIR
（本次检索基于用户作品认领结果）

浏览/检索结果: 共25条，第1-10条 帮助

限定条件        
已选(0)清除 条数/页：   排序方式：
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：104/0  |  提交时间：2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance  
Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma 期刊论文
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 卷号: 5
作者:  Liu, Juan;  Liang, Qianmao;  Wang, Aoli;  Zou, Fengming;  Qi, Ziping;  Yu, Kailin;  Liu, Qingwang;  Chen, Cheng;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：51/0  |  提交时间：2020/11/30
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Chen, Cheng;  Cheng, Chuan-dong;  Wu, Hong;  Wang, Zuo-wei;  Wang, Li;  Jiang, Zong-ru;  Wang, Ao-li;  Hu, Chen;  Dong, Yong-fei;  Niu, Wan-xiang;  Qi, Shuang;  Qi, Zi-ping;  Liu, Jing;  Wang, Wen-chao;  Niu, Chao-shi;  Liu, Qing-song
浏览  |  Adobe PDF(3476Kb)  |  收藏  |  浏览/下载：101/36  |  提交时间：2020/11/26
glioblastoma  osimertinib  temozolamide  MAPK-signaling pathway  MNK  eukaryotic translation initiation factor 4E  
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping;  Hu, Chen;  Wang, Wenliang;  Wu, Hong;  Huang, Tao;  Zhao, Ming;  Wang, Wenchao;  Hu, Zhenquan;  Liu, Qingwang;  Wang, Beilei;  Wang, Li;  Li, Lili;  Ge, Jian;  Ren, Tao;  Xia, Ruixiang;  Liu, Jing
收藏  |  浏览/下载：58/0  |  提交时间：2019/11/27
BCR-ABL  PDGFR  chronic myeloid leukemia  kinase inhibitor  
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: 62, 期号: 2, 页码: 875-892
作者:  Liang, Xiaofei;  Wang, Beilei;  Chen, Cheng;  Wang, Aoli;  Hu, Chen;  Zou, Fengming;  Yu, Kailin;  Liu, Qingwang;  Li, Feng;  Hu, Zhenquan;  Lu, Tingting;  Wang, Junjie;  Wang, Li;  Weisberg, Ellen L.;  Li, Lili;  Xia, Ruixiang;  Wang, Wenchao;  Ren, Tao;  Ge, Jian;  Liu, Jing;  Liu, Qinsong
浏览  |  Adobe PDF(13868Kb)  |  收藏  |  浏览/下载：377/322  |  提交时间：2020/05/21
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models 期刊论文
CANCER LETTERS, 2019, 页码: 105-114
作者:  Lu, Tingting;  Chen, Cheng;  Wang, Aoli;  Jiang, Zongru;  Qi, Ziping;  Hu, Zhenquan;  Hu, Chen;  Liu, Feiyang;  Wang, Wenliang;  Wu, Hong;  Wang, Beilei;  Wang, Li;  Qi, Shuang;  Wu, Jiaxin;  Wang, Wenchao;  Tang, Jun;  Yan, Hezhong;  Bai, Mingfeng;  Liu, Qingsong;  Liu, Jing
收藏  |  浏览/下载：26/0  |  提交时间：2020/07/14
cKIT T670I mutant  Activation loop mutants  Drug resistance  
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 160, 页码: 61-81
作者:  Liu, Xuesong;  Wang, Beilei;  Chen, Cheng;  Jiang, Zongru;  Hu, Chen;  Wu, Hong;  Zhang, Yicong;  Liu, Xiaochuan;  Wang, Wenliang;  Wang, Junjie;  Hu, Zhenquan;  Wang, Aoli;  Huang, Tao;  Liu, Qingwang;  Wang, Wei;  Wang, Li;  Wang, Wenchao;  Ren, Tao;  Li, Lili;  Xia, Ruixiang;  Ge, Jian;  Liu, Qingsong;  Liu, Jing
Adobe PDF(4593Kb)  |  收藏  |  浏览/下载：195/104  |  提交时间：2019/01/11
ABL kinase  Kinase inhibitor  ABL mutant  CML  
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino) cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl) tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 158, 页码: 896-916
作者:  Wang, Beilei;  Wu, Jiaxin;  Wu, Yun;  Chen, Cheng;  Zou, Fengming;  Wang, Aoli;  Wu, Hong;  Hu, Zhenquan;  Jiang, Zongru;  Liu, Qingwang;  Wang, Wei;  Zhang, Yicong;  Liu, Feiyang;  Zhao, Ming;  Hu, Jie;  Huang, Tao;  Ge, Juan;  Wang, Li;  Ren, Tao;  Wang, Yuxin;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：28/0  |  提交时间：2019/12/25
CDK9  Kinase inhibitor  Structure-activity relationship  Leukemia  
Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrinnido[5,4-b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 61, 期号: 10, 页码: 4608-4627
作者:  Xue, Yu;  Song, Peiran;  Song, Zilan;  Wang, Aoli;  Tong, Linjiang;  Geng, Meiyu;  Ding, Jian;  Liu, Qingsong;  Sun, Liping;  Xie, Hua;  Zhang, Ao
浏览  |  Adobe PDF(6587Kb)  |  收藏  |  浏览/下载：151/107  |  提交时间：2019/08/23
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFR alpha kinase inhibitor for PDGFR alpha driving chronic eosinophilic leukemia 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 150, 期号: 无, 页码: 366-384
作者:  Wang, Qiang;  Liu, Feiyang;  Qi, Shuang;  Qi, Ziping;  Yan, Xiao-E.;  Wang, Beilei;  Wang, Aoli;  Wang, Wei;  Chen, Cheng;  Liu, Xiaochuan;  Jiang, Zongru;  Hu, Zhenquan;  Wang, Li;  Wang, Wenchao;  Ren, Tao;  Zhang, Shanchun;  Yun, Cai-Hong;  Liu, Qingsong;  Liu, Jing
浏览  |  Adobe PDF(5108Kb)  |  收藏  |  浏览/下载：596/506  |  提交时间：2019/06/10
PDGFR kinase  Type II inhibitor  Kinase inhibitor  CEL